Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301554 | 0.83 | SCN10A (0.37) | SCN10APARP1ALDH1A1SCN2ASCN9A | |
| SCHEMBL31301330 | 0.83 | GRM1 (0.39) | SCN10APARP1ALDH1A1L3MBTL1SCN9A | |
| SCHEMBL31301619 | 0.80 | MLYCD (0.46) | SCN10APARP1SCN2ASCN9A | |
| SCHEMBL31301297 | 0.80 | GPBAR1 (0.40) | SCN10APARP1L3MBTL1SCN2ASCN9A | |
| SCHEMBL31301329 | 0.80 | SCN10A (0.39) | SCN10APARP1L3MBTL1SCN2ASCN9A | |
| SCHEMBL31301631 | 0.78 | ALDH1A1 (0.36) | SCN10APARP1ALDH1A1L3MBTL1SCN2A | |
| SCHEMBL31301363 | 0.78 | GPBAR1 (0.42) | SCN10APARP1SCN9AGRM1 | |
| SCHEMBL31301441 | 0.77 | SMN1; SMN2 (0.53) | SCN10ASCN2ANPC1 | |
| SCHEMBL31301681 | 0.77 | MPL (0.38) | SCN10APARP1SCN9A | |
| SCHEMBL31301305 | 0.77 | SCN10A (0.37) | SCN10APARP1SCN2ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | CTSA 1165/4885SCN10A 3171/4885PARP1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.